NewAmsterdam Pharma (NAMS) Current Leases (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Current Leases of $23000.0 for Q1 2026, down 83.09% sequentially from $136000.0 in Q4 2025, and down 90.87% YoY from $252000.0 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Current Leases (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Current Leases for 6 years, with the latest figure at $23000.0 in Q1 2026.
- Quarterly Current Leases fell 90.87% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (down 90.87% YoY) and the FY2025 annual result came in at $136000.0, down 44.72% from the prior year.
- Current Leases eased to $23000.0 in Q1 2026 per NAMS's latest filing, from $136000.0 in the prior quarter.
- Over five years, Current Leases peaked at $252000.0 in Q1 2025 and troughed at $23000.0 in Q1 2026.
- A 5-year average of $147745.5 and a median of $158500.0 in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2025 and 2026: Current Leases soared 486.05% in 2025, then sank 90.87% in 2026.
- Over 5 years, Current Leases stood at $63255.3 in 2022, then fell by 5.15% to $60000.0 in 2023, then soared by 310.0% to $246000.0 in 2024, then sank by 44.72% to $136000.0 in 2025, then sank by 83.09% to $23000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $23000.0, $136000.0, and $181000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | 26,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 136,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | 252,000.00 |
| Dec 31, 2024 | 246,000.00 |
| Sep 30, 2024 | 240,000.00 |
| Jun 30, 2024 | 234,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 60,000.00 |
| Jun 30, 2023 | 69,691.16 |
| Dec 31, 2022 | 63,255.34 |
| Dec 31, 2021 | 60,630.46 |